Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of AMG 334 (erenumab) for Migraine Prevention
2012-005331-90Phase 2Completed
- Sponsor
- Amgen
- Start
- Apr 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of erenumab in migraine, sponsored by Amgen. Started Apr 2013; status: completed.
02
Drugs
erenumab
03
Conditions
migraine
Beyond the preview
Go deeper on 2012-005331-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005331-90.